In a prospective phase 1 trial, nivolumab (anti–PD-1) modulated HIV-specific CD8+ T-cell phenotypes in men with HIV who were also receiving suppressive antiretroviral therapy and had advanced solid tumors. Longitudinal peripheral blood analyses using HIV peptide:MHC-I tetramers showed dynamic changes after single and repeated dosing. The study reports measurable shifts in both cellular composition and transcriptional activity, supporting that PD-1 blockade can alter antigen-specific memory T-cell states in vivo. While immune checkpoint blockade is being investigated across chronic infections for exhaustion reversal, the trial provides direct evidence in the HIV setting. The findings also highlight ongoing interest in whether immune remodeling can translate into meaningful effects on HIV latency and the reservoir, even as clinical outcomes remain to be proven.
Get the Daily Brief